The optimal treatment of clinically negative inguinal lymph nodes in patients with primary anal cancer has not yet been clearly defined. The presence of metastases in the inguinal lymph nodes is an adverse prognostic factor for anal cancer. In the present study the feasibility of sentinel lymph node biopsy (SLNB) for staging anal cancer was investigated.
INTRODUCTION
Anal cancer is rare and only accounts for 1-2 % of all lower digestive tract cancers (1). The goals in the treatment of anal cancer are cure and locoregional control with sphincter salvage. During the last three decades multimodality treatment with combination of irradiation, chemotherapy and surgery has become the standard of care (2). This approach has improved overall survival, colostomy-free survival and locore-gional control without increasing morbidity and mortality (3-5).
Inguinal lymph nodes can be involved in anal cancer. Metastases to the inguinal lymph nodes occur in 15-25 % of patients (6). The presence of inguinal lymph node metastases is an independent prognostic factor for both locoregional failure and overall survival (7). The treatment of the inguinal lymph node area in patients with anal cancer varies greatly (3-5, 8-10). The morbidity associated with elective (prophylactic) groin dissection outweighs the expected staging benefit and this procedure is not used widely for anal cancer (1, 6).
Sentinel lymph node biopsy (SLNB) is a minimally invasive surgical staging procedure. The aim of this study was to define whether the sentinel node concept can be applied to the staging of patients with anal cancer.
PATIENTS AND METHODS
From September 1999 patients with biopsy proven primary anal cancer underwent dual-agent guided SLNB for inguinal nodal staging before starting multimodality treatment. Informed consent was obtained from each patient. For clinical staging of the groins palpation, ultrasonography and if needed aspiration cytology were performed. Unilateral inguinal lymph node metastasis was confirmed by clinical staging in only one patient.
Lymphoscintigraphy and surgery: 99m Technecium (Tc) labeled colloidal human serum albumin with particle size of 200-600 nm (Senti-Scint, NCPH-NRIRR, Budapest, Hungary) was injected in 0,4 ml volume peritumorally in 4 depots in the afternoon prior to surgery. The injected dose was 30 MBq. Patients were imaged using gamma camera (Toshiba GCA-7100A, Toshiba Corp., Shimoishigami, Japan) with low energy high resolution collimator next morning. Antero-posterior static images were taken and hot spots in the groin(s) were marked on the overlying skin with indelible ink. After lymphoscintigraphy patients were transported to the operating room. Patent blue dye (Patentblau V 2,5 %, Byk Gulden Konstanz, Germany) in 2 ml volume was injected 10 minutes before surgery peritumorally in 4 depots. Two types of intraoperative gammaprobes were used (Navigator GPS, USSC Norwalk, CT, USA or Europrobe, Eurorad, Strasbourg, France) to localize the sentinel lymph nodes (SLNs) intraoperatively. SLNB was performed under general anaesthesia with a combination of probe-guided surgery and blue dye lymphatic mapping. Early therapeutic (selective) inguinal lymphadenctomy was performed in SLN positive patients.
Pathologic examination: SLNs were evaluated at 1 mm levels by routine hematoxylin and eosin (H&E) staining.
RESULTS
From September 1999 to March 2002, 8 patients (5 female and 3 male, mean age 59,5 (47-68) years) with biopsy proven primary sqamous cell cancer of the anus underwent lymphoscintigraphy and dual-agent guided inguinal SLNB for nodal staging before starting multimodality treatment.
Bilateral inguinal drainage was observed in 5 patients and unilateral in 3. SLNB was successful in all 8 patients (13 groins). A total of 20 hot and blue SLNs (mean 1,5 (1-2) per groins) were removed. In 2 patients (25 %) with bilateral inguinal drainage the SLN was positive for metastasis. Metastasis was unilateral and SLN was the only metastatic lymph node in each case. Metastases in the SLNs were 1 and 3 mm in size. In the patient with clinically evident metastasis in the left groin (lymphoscintigraphy showed no lymphatic drainage toward this side) no metastasis was detected in the SLN in the right groin.
Neither general nor surgical complications were observed in these patients. In the follow-up period (5-35 months) no patient died and no inguinal recurrence occurred. Abdominoperineal rectum exstirpation was performed in 3 patients because of local treatment failure.
DISCUSSION
Because squamous cell cancer of the anus has a low tendency to disseminate, locoregional control is of major importance to the outcome of patients (6). Multimodality treatment with combination of irradiation, chemotherapy and surgery has improved overall survival, colostomy-free survival and locoregional control of these patients without increasing morbidity and mortality (3-5).
The optimal management of clinically negative inguinal lymph nodes in patients with primary anal cancer is still controversial (3-5, 8-10) . The presence of metastases in the inguinal lymph nodes is an adverse prognostic factor for anal cancer (7). Bilateral (or unilateral) elective (prophylactic) inguinal lymphadenectomy is not advocated because of its high morbidity rate which outweighs the expected staging benefit for histologically node negative patients (1, 6) .
The wait-and-see policy with close follow-up and careful examination to detect inguinal lymph node recurrence is the simplest approach (6, 8, 9) but, in about 20 % of patients, clinically evident metachronous inguinal lymph node metastases will occur and may lead to metastatic disease. Metachronous inguinal recurrence can be controlled with multimodality treatment in about 50 % of patients. In some institutions elective irradiation of bilateral ilioinguinal lymph nodes is performed (3, 4, 10). This treatment provides regional control in the absence of local recurrence to more than 95 % of patients. However, this type of treatment can cause life-threatening acute complications and can lead to necrosis of the femoral head and stenosis of the iliac arteries (3, 4). Thus routine elective irradiation of bilateral ilioinguinal areas may not be recommended to all patients (6).
SLNB may be a good approach for staging patients with anal cancer. To our knowledge this is the third study reporting on SLNB for anal cancer. In a case report by Keshtgar and co-workers (11) SLNB was successfully performed in one patient, and in an other study on inguinal lymph node metastases in anal canal cancer by Gerard and co-workers (6) SLNB was successfully performed in 13 patients. In the present study inguinal SLNB was performed in 8 patients with primary anal cancer. The surgical identification rate was 100 % and metastasis was detected in 2 patients. SLNB was also successfully performed on the contralateral groin in the patient with clinically evident unilateral inguinal lymph node metastasis. The accuracy of SLNB cannot be given because completion groin dissection has not been performed in patients with negative SLN(s) and/or with clinically negative groin without lymphatic drainage on lymphoscintigraphy (this would have been unethical). The accuracy of SLNB can only be determined by long term follow-up of these patients.
At present the optimal management of the inguinal lymph nodes in SLN positive patients cannot be defined. In this study early therapeutic (selective) inguinal lymphadenectomy was performed in the 2 patients with positive SLN. In the study by Gerard and co-workers (6) the inguinal area in the 2 patients with positive SLN was selectively irradiated.
In conclusion, lymphoscintigraphy with dualagent guided inguinal SLNB has proved to be tech-nically feasible for staging patients with anal cancer. The histological result of SLNB may alter the treatment of these patients, and thus improves survival, locoregional control and quality of life, and minimizes treatment related morbidity. The optimal management of the inguinal lymph nodes (lymphadenectomy versus irradiation versus both) in patients with positive SLN(s) cannot be defined at present. Further studies are needed to answer these clinical questions.
